CSL Shares Drop to Nine-Year Low as Selloff Deepens

CSL shares (ASX: CSL) hit their lowest level since December 2017 on Monday, closing at A$142.22 after touching an intraday low of A$140.93, as markets continue to punish the biotech giant for a string of profit warnings, strategic missteps and abrupt leadership changes that have shattered its reputation as one of Australia’s most dependable growth stocks.

The 2.77% decline extends a brutal selloff that has seen CSL shares drop 44.3% over the past twelve months and 17.29% year-to-date in 2026, wiping approximately A$54 billion from the company’s market capin 12 months. The CSL share price now trades at levels last seen when revenue was roughly half its current size, marking a complete reversal of fortune for a company that spent two decades delivering consistent double-digit earnings growth.

CSL Shares Stair Stepping Lower

Three major downward “stair steps” have defined CSL’s collapse, clearly visible on the 1 year chart above. The first came in August 2025, when the company unveiled its full-year results alongside a sweeping transformation program that included plans to cut roughly 3,000 jobs and demerge its Seqirus influenza vaccine business. Despite reporting fiscal 2025 net profit growth of 17% to approximately US$3.0 billion on revenue of US$15.6 billion, markets focused on weaker-than-expected guidance for fiscal 2026, with revenue growth projected at just 4-5% and underlying profit growth of 7-10%, well below the high-teens compounding that had characterised the previous decade. The stock plunged 16% in a single session, its largest one-day fall in the company’s listed history.

The second blow landed at the October 2025 annual general meeting, when CSL slashed its medium-term outlook barely ten weeks after the August reset. Management cut fiscal 2026 revenue growth guidance to 2-3% and profit growth to 4-7%, while downgrading fiscal 2027-28 expectations from low-double-digit growth to “high single digits.” The company also reversed course on the planned Seqirus demerger, citing heightened volatility in the US influenza vaccine market, where vaccination rates had fallen approximately 12% overall and 14% in the crucial over-65 demographic. Markets reacted with another 13-14% single-day decline, pushing the stock to a six-year low and raising questions about strategic consistency and management credibility.

The third and most damaging episode unfolded in February 2026. On February 10, CSL announced that chief executive Paul McKenzie would retire immediately, with former Seqirus president Gordon Naylor appointed as interim CEO. The abrupt departure came one day before the company’s half-year fiscal 2026 results, widely interpreted as the board losing confidence in execution of the transformation program. The following day’s earnings release confirmed the extent of the crisis: while underlying profit fell a modest 7% to US$1.95 billion on revenue of US$8.3 billion, statutory net profit collapsed roughly 86% to US$286 million due to approximately US$1.1 billion in impairments and restructuring charges. The write-downs spanned mRNA vaccine assets, Vifor pharmaceutical products facing generic competition, redundant manufacturing facilities and Seqirus-related adjustments, calling into question the strategic rationale and execution of the US$11.7 billion Vifor acquisition completed in 2022.

Breaking down the divisional performance, CSL’s core plasma therapies business which accounts for roughly 60% of group revenue and has historically been the profit engine, saw revenue decline 7% and earnings fall 9% in the half. Immunoglobulin revenue dropped to approximately US$3.0 billion, pressured by US Medicare payment reforms that cost the company an estimated US$100 million in the period, alongside weaker demand for albumin in China. The Seqirus vaccine division posted a 2% revenue decline as the softer US flu season materialised, while Vifor managed slight revenue growth and 22% operating profit expansion, though from a low base and against a backdrop of looming patent expiries on key nephrology products.

Management reaffirmed fiscal 2026 guidance despite the weak first half, projecting the business will deliver 2-3% revenue growth and 4-7% underlying profit growth at constant currency for the full year. The company also expanded its on-market share buyback from US$500 million to US$750 million, with approximately US$400 million already executed, and maintained the interim dividend at US$1.30 per share. These capital management initiatives are designed to signal confidence and support earnings per share metrics as the absolute profit pool stagnates, though critics argue the buyback merely papers over deeper operational challenges.

Perhaps most damaging to the bull case is the erosion of management credibility. CSL spent decades cultivating a reputation for conservative guidance and consistent delivery, with the August and October downgrades representing the first material negative surprises in recent memory. The rapid succession of CEO and CFO departures raises questions about the depth of leadership talent and whether the board fully grasps the scale of the operational and strategic challenges. Interim CEO Gordon Naylor brings deep Seqirus experience but lacks a track record running the integrated group, and the extended search for a permanent replacement creates an execution vacuum at a critical juncture.

CSL’s fall from grace serves as a stark reminder that even the highest-quality franchises are not immune to cyclical pressures, strategic missteps and execution failures, leaving markets to weigh whether the current price represents a rare opportunity to buy a world-class business at a decade-low valuation, or a value trap where further downgrades and margin compression lie ahead before the turnaround gains traction.